Semaglutide Cuts Asthma and COPD Attacks in Large Study
A large-scale study links semaglutide to reduced asthma and COPD exacerbations, prompting calls for clinical trials to confirm these respiratory benefits.
Atlas Newsdesk ·
Recent observational data indicate that semaglutide, the active ingredient in GLP-1 receptor agonists, is associated with a 40% reduction in asthma attacks and a 20% reduction in COPD flare-ups. The study analyzed electronic health records of approximately 80,000 patients comparing GLP-1 therapies against alternative diabetes medications.
These findings suggest potential secondary clinical benefits for patients with metabolic dysfunction and concurrent airway diseases. The observed anti-inflammatory effects warrant further investigation into the systemic impact of metabolic therapies on respiratory health.
Despite the statistical correlation, researchers caution that these results do not currently support off-label prescribing for respiratory conditions. Clinical trials incorporating respiratory outcomes are required to validate these findings and determine if metabolic interventions should be integrated into standard respiratory care protocols.